This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Targeting the epidermal growth factor receptor in egfr-mutated lung cancer: Current and emerging therapies
Cancers. 2021 Jun 24;13(13)
PMID: 34202748 PMCID: PMC8267708 URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108437120&doi=10.3390%2fcancers13133164&partnerID=40&md5=a8a9e303ed65bf88b0ab989940266cb1
AbstractEpidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with EGFR-mutated metastatic lung cancer. While EGFR TKIs have initially high response rates, inherent and acquired resistance constitute a major challenge to the longitudinal treatment. Ongoing work is aimed at understanding the molecular basis of these resistance mechanisms, with exciting new studies evaluating novel agents and combination therapies to improve control of tumors with all forms of EGFR mutation. In this review, we first provide a discussion of EGFR-mutated lung cancer and the efficacy of available EGFR TKIs in the clinical setting against both common and rare EGFR mutations. Second, we discuss common resistance mechanisms that lead to therapy failure during treatment with EGFR TKIs. Third, we review novel approaches aimed at improving outcomes and overcoming resistance to EGFR TKIs. Finally, we highlight recent breakthroughs in the use of EGFR TKIs in non-metastatic EGFR-mutated lung cancer.
NotesExport Date: 1 July 2021